简介内容:RET-IN-22 (compound 17b) is a potent, selective, and orally active inhibitor of RET, exhibiting IC50 values of nM for wild-type RET and nM for RET-V804M. It demonstrates a highly selective inhibition profile across a broad spectrum of kinases, with notable specificity over EGFR and VEGFR2. Additionally, RET-IN-22 is implicated in exerting anticancer effects [1].